BusinessFDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical DirectorBy Nasdaq OMXMay 7, 2018, 4:27 PM UTC
BusinessRegentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis TreatmentBy Nasdaq OMXFeb 14, 2018, 12:00 PM UTC
BusinessRegentys Names Dr. John F. Howes Vice President of Clinical and Regulatory AffairsBy Nasdaq OMXJan 9, 2018, 12:31 PM UTC
BusinessThetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBDBy Nasdaq OMXDec 11, 2017, 3:35 PM UTC
BusinessThetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel DiseaseBy Nasdaq OMXNov 16, 2017, 5:35 PM UTC
BusinessInnovate Biopharma’s Pediatric Ulcerative Colitis Drug Granted FDA Orphan DesignationBy Nasdaq OMXSep 6, 2017, 9:06 PM UTC
BusinessInnovate Biopharmaceuticals Submits Orphan Drug Application to FDA for Pediatric Ulcerative Colitis IndicationBy Nasdaq OMXJul 12, 2017, 11:07 AM UTC
BusinessAtlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative ColitisBy Nasdaq OMXMay 30, 2017, 12:28 PM UTC
